Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free AKBA Stock Alerts

Akebia Therapeutics (AKBA) Competitors

Akebia Therapeutics logo
$1.45 -0.05 (-3.33%)
Closing price 04:00 PM Eastern
Extended Trading
$1.48 +0.03 (+2.07%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AKBA vs. IMTX, MBX, DMRA, BHVN, and IMCR

Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Immatics (IMTX), MBX Biosciences (MBX), Damora Therapeutics, Inc. Common Stock (DMRA), Biohaven (BHVN), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.

How does Akebia Therapeutics compare to Immatics?

Akebia Therapeutics (NASDAQ:AKBA) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Akebia Therapeutics currently has a consensus price target of $4.67, suggesting a potential upside of 221.84%. Immatics has a consensus price target of $19.00, suggesting a potential upside of 73.52%. Given Akebia Therapeutics' higher probable upside, equities analysts clearly believe Akebia Therapeutics is more favorable than Immatics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Immatics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Akebia Therapeutics has higher revenue and earnings than Immatics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akebia Therapeutics$236.20M1.65-$5.34M-$0.02N/A
Immatics$48.27M30.42-$222.26M-$1.84N/A

Akebia Therapeutics has a net margin of -2.26% compared to Immatics' net margin of -411.90%. Akebia Therapeutics' return on equity of -16.70% beat Immatics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akebia Therapeutics-2.26% -16.70% -1.53%
Immatics -411.90%-41.81%-34.72%

In the previous week, Akebia Therapeutics had 3 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Akebia Therapeutics and 3 mentions for Immatics. Akebia Therapeutics' average media sentiment score of 0.29 beat Immatics' score of -0.25 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akebia Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Immatics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Akebia Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Immatics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Summary

Akebia Therapeutics beats Immatics on 10 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to MBX Biosciences?

Akebia Therapeutics (NASDAQ:AKBA) and MBX Biosciences (NASDAQ:MBX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Akebia Therapeutics currently has a consensus price target of $4.67, suggesting a potential upside of 221.84%. MBX Biosciences has a consensus price target of $53.25, suggesting a potential upside of 79.90%. Given Akebia Therapeutics' higher possible upside, research analysts clearly believe Akebia Therapeutics is more favorable than MBX Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.75

Akebia Therapeutics has higher revenue and earnings than MBX Biosciences. Akebia Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akebia Therapeutics$236.20M1.65-$5.34M-$0.02N/A
MBX BiosciencesN/AN/A-$86.97M-$2.41N/A

MBX Biosciences has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -2.26%. Akebia Therapeutics' return on equity of -16.70% beat MBX Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Akebia Therapeutics-2.26% -16.70% -1.53%
MBX Biosciences N/A -28.72%-27.55%

Akebia Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, MBX Biosciences has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

33.9% of Akebia Therapeutics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Akebia Therapeutics had 6 more articles in the media than MBX Biosciences. MarketBeat recorded 6 mentions for Akebia Therapeutics and 0 mentions for MBX Biosciences. Akebia Therapeutics' average media sentiment score of 0.29 beat MBX Biosciences' score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Akebia Therapeutics Neutral
MBX Biosciences Neutral

Summary

Akebia Therapeutics beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Akebia Therapeutics (NASDAQ:AKBA) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akebia Therapeutics$236.20M1.65-$5.34M-$0.02N/A
Damora Therapeutics, Inc. Common StockN/AN/A-$209.84M-$12.10N/A

Akebia Therapeutics currently has a consensus price target of $4.67, suggesting a potential upside of 221.84%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $43.40, suggesting a potential upside of 74.51%. Given Akebia Therapeutics' higher possible upside, research analysts clearly believe Akebia Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Damora Therapeutics, Inc. Common Stock
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -2.26%. Akebia Therapeutics' return on equity of -16.70% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company Net Margins Return on Equity Return on Assets
Akebia Therapeutics-2.26% -16.70% -1.53%
Damora Therapeutics, Inc. Common Stock N/A -147.05%-279.49%

In the previous week, Akebia Therapeutics had 3 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for Akebia Therapeutics and 3 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.02 beat Akebia Therapeutics' score of 0.29 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akebia Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Damora Therapeutics, Inc. Common Stock
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Akebia Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Summary

Akebia Therapeutics and Damora Therapeutics, Inc. Common Stock tied by winning 8 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Biohaven?

Biohaven (NYSE:BHVN) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

88.8% of Biohaven shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Comparatively, 3.0% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than Biohaven. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiohavenN/AN/A-$738.82M-$6.96N/A
Akebia Therapeutics$236.20M1.65-$5.34M-$0.02N/A

Biohaven presently has a consensus price target of $22.47, indicating a potential upside of 131.45%. Akebia Therapeutics has a consensus price target of $4.67, indicating a potential upside of 221.84%. Given Akebia Therapeutics' higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Biohaven.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biohaven
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
2.78
Akebia Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Biohaven has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -2.26%. Akebia Therapeutics' return on equity of -16.70% beat Biohaven's return on equity.

Company Net Margins Return on Equity Return on Assets
BiohavenN/A -688.89% -158.04%
Akebia Therapeutics -2.26%-16.70%-1.53%

In the previous week, Biohaven had 4 more articles in the media than Akebia Therapeutics. MarketBeat recorded 10 mentions for Biohaven and 6 mentions for Akebia Therapeutics. Biohaven's average media sentiment score of 0.82 beat Akebia Therapeutics' score of 0.29 indicating that Biohaven is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biohaven
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Akebia Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Biohaven has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Summary

Biohaven beats Akebia Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Akebia Therapeutics has lower revenue, but higher earnings than Immunocore. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immunocore$400.02M3.65-$35.51M-$0.70N/A
Akebia Therapeutics$236.20M1.65-$5.34M-$0.02N/A

84.5% of Immunocore shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 10.4% of Immunocore shares are held by company insiders. Comparatively, 3.0% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Akebia Therapeutics has a net margin of -2.26% compared to Immunocore's net margin of -8.88%. Immunocore's return on equity of -9.20% beat Akebia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Immunocore-8.88% -9.20% -3.32%
Akebia Therapeutics -2.26%-16.70%-1.53%

Immunocore presently has a consensus price target of $60.89, indicating a potential upside of 111.13%. Akebia Therapeutics has a consensus price target of $4.67, indicating a potential upside of 221.84%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Immunocore.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunocore
2 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.36
Akebia Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Akebia Therapeutics had 1 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for Akebia Therapeutics and 5 mentions for Immunocore. Akebia Therapeutics' average media sentiment score of 0.29 beat Immunocore's score of 0.28 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunocore
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Akebia Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Summary

Immunocore and Akebia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKBA vs. The Competition

Export
MetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$388.96M$3.10B$6.25B$11.87B
Dividend YieldN/A1.91%2.73%5.21%
P/E Ratio-72.4618.3729.0428.47
Price / Sales1.65281.31476.6160.94
Price / CashN/A50.4327.6236.52
Price / Book12.084.339.676.67
Net Income-$5.34M$72.19M$3.55B$332.53M
7 Day Performance2.11%2.02%1.70%2.01%
1 Month Performance5.07%6.41%5.62%9.20%
1 Year Performance-38.03%37.73%34.42%39.59%

Akebia Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKBA
Akebia Therapeutics
2.5056 of 5 stars		$1.45
-3.3%		$4.67
+221.8%		N/A$388.96M$236.20MN/A430
IMTX
Immatics
2.149 of 5 stars		$11.35
flat		$19.00
+67.4%		N/A$1.52B$54.60MN/A260
MBX
MBX Biosciences
2.3707 of 5 stars		$31.97
+0.0%		$53.25
+66.6%		N/A$1.52BN/AN/AN/A
DMRA
Damora Therapeutics, Inc. Common Stock
2.8181 of 5 stars		$25.50
+3.0%		$43.40
+70.2%		N/A$1.49BN/AN/A40
BHVN
Biohaven
2.6958 of 5 stars		$9.59
-2.9%		$22.53
+134.9%		N/A$1.49BN/AN/A239

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AKBA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel